Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

John G. Gribben, David Zahrieh, Katherine Stephans, Lini Bartlett-Pandite, Edwin P. Alyea, David C. Fisher, Arnold S. Freedman, Peter Mauch, Robert Schlossman, Lecia V. Sequist, Robert J. Soiffer, Blossom Marshall, Donna Neuberg, Jerome Ritz, Lee M. Nadler

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

We report here on the long-term follow-up on 162 patients with high-risk chronic lymphocytic leukemia (CLL) who have undergone hematopoietic stem cell transplantation (SCT) at a single center from 1989 to 1999. Twenty-five patients with human leukocyte antigen (HLA)-matched sibling donors underwent T-cell-depleted allogeneic SCT, and 137 patients without HLA-matched sibling donors underwent autologous SCT. The 100-day mortality was 4% for both groups, but later morbidity and mortality were negatively affected on outcome. Progression-free survival was significantly longer following autologous than allogeneic SCT, but there was no difference in overall survival and no difference in the cumulative incidence of disease recurrence or deaths without recurrence between the 2 groups. At a median follow-up of 6.5 years there is no evidence of a plateau of progression-free survival. The majority of patients treated with donor lymphocyte infusions after relapse responded, demonstrating a significant graft-versus-leukemia effect in CLL. From these findings we have altered our approach for patients with high-risk CLL and are currently exploring the role of related and unrelated allogeneic SCT following reduced-intensity conditioning regimens.

Original languageEnglish (US)
Pages (from-to)4389-4396
Number of pages8
JournalBlood
Volume106
Issue number13
DOIs
StatePublished - Dec 15 2005
Externally publishedYes

Fingerprint

Stem Cell Transplantation
B-Cell Chronic Lymphocytic Leukemia
Stem cells
Tissue Donors
HLA Antigens
Recurrence
Disease-Free Survival
Siblings
T-cells
Lymphocytes
Mortality
Hematopoietic Stem Cell Transplantation
Grafts
Leukemia
Morbidity
T-Lymphocytes
Transplants
Survival
Incidence

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Gribben, J. G., Zahrieh, D., Stephans, K., Bartlett-Pandite, L., Alyea, E. P., Fisher, D. C., ... Nadler, L. M. (2005). Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood, 106(13), 4389-4396. https://doi.org/10.1182/blood-2005-05-1778

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. / Gribben, John G.; Zahrieh, David; Stephans, Katherine; Bartlett-Pandite, Lini; Alyea, Edwin P.; Fisher, David C.; Freedman, Arnold S.; Mauch, Peter; Schlossman, Robert; Sequist, Lecia V.; Soiffer, Robert J.; Marshall, Blossom; Neuberg, Donna; Ritz, Jerome; Nadler, Lee M.

In: Blood, Vol. 106, No. 13, 15.12.2005, p. 4389-4396.

Research output: Contribution to journalArticle

Gribben, JG, Zahrieh, D, Stephans, K, Bartlett-Pandite, L, Alyea, EP, Fisher, DC, Freedman, AS, Mauch, P, Schlossman, R, Sequist, LV, Soiffer, RJ, Marshall, B, Neuberg, D, Ritz, J & Nadler, LM 2005, 'Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia', Blood, vol. 106, no. 13, pp. 4389-4396. https://doi.org/10.1182/blood-2005-05-1778
Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005 Dec 15;106(13):4389-4396. https://doi.org/10.1182/blood-2005-05-1778
Gribben, John G. ; Zahrieh, David ; Stephans, Katherine ; Bartlett-Pandite, Lini ; Alyea, Edwin P. ; Fisher, David C. ; Freedman, Arnold S. ; Mauch, Peter ; Schlossman, Robert ; Sequist, Lecia V. ; Soiffer, Robert J. ; Marshall, Blossom ; Neuberg, Donna ; Ritz, Jerome ; Nadler, Lee M. / Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. In: Blood. 2005 ; Vol. 106, No. 13. pp. 4389-4396.
@article{f567b903e501412caa9af6f8b9b3c2cd,
title = "Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia",
abstract = "We report here on the long-term follow-up on 162 patients with high-risk chronic lymphocytic leukemia (CLL) who have undergone hematopoietic stem cell transplantation (SCT) at a single center from 1989 to 1999. Twenty-five patients with human leukocyte antigen (HLA)-matched sibling donors underwent T-cell-depleted allogeneic SCT, and 137 patients without HLA-matched sibling donors underwent autologous SCT. The 100-day mortality was 4{\%} for both groups, but later morbidity and mortality were negatively affected on outcome. Progression-free survival was significantly longer following autologous than allogeneic SCT, but there was no difference in overall survival and no difference in the cumulative incidence of disease recurrence or deaths without recurrence between the 2 groups. At a median follow-up of 6.5 years there is no evidence of a plateau of progression-free survival. The majority of patients treated with donor lymphocyte infusions after relapse responded, demonstrating a significant graft-versus-leukemia effect in CLL. From these findings we have altered our approach for patients with high-risk CLL and are currently exploring the role of related and unrelated allogeneic SCT following reduced-intensity conditioning regimens.",
author = "Gribben, {John G.} and David Zahrieh and Katherine Stephans and Lini Bartlett-Pandite and Alyea, {Edwin P.} and Fisher, {David C.} and Freedman, {Arnold S.} and Peter Mauch and Robert Schlossman and Sequist, {Lecia V.} and Soiffer, {Robert J.} and Blossom Marshall and Donna Neuberg and Jerome Ritz and Nadler, {Lee M.}",
year = "2005",
month = "12",
day = "15",
doi = "10.1182/blood-2005-05-1778",
language = "English (US)",
volume = "106",
pages = "4389--4396",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

AU - Gribben, John G.

AU - Zahrieh, David

AU - Stephans, Katherine

AU - Bartlett-Pandite, Lini

AU - Alyea, Edwin P.

AU - Fisher, David C.

AU - Freedman, Arnold S.

AU - Mauch, Peter

AU - Schlossman, Robert

AU - Sequist, Lecia V.

AU - Soiffer, Robert J.

AU - Marshall, Blossom

AU - Neuberg, Donna

AU - Ritz, Jerome

AU - Nadler, Lee M.

PY - 2005/12/15

Y1 - 2005/12/15

N2 - We report here on the long-term follow-up on 162 patients with high-risk chronic lymphocytic leukemia (CLL) who have undergone hematopoietic stem cell transplantation (SCT) at a single center from 1989 to 1999. Twenty-five patients with human leukocyte antigen (HLA)-matched sibling donors underwent T-cell-depleted allogeneic SCT, and 137 patients without HLA-matched sibling donors underwent autologous SCT. The 100-day mortality was 4% for both groups, but later morbidity and mortality were negatively affected on outcome. Progression-free survival was significantly longer following autologous than allogeneic SCT, but there was no difference in overall survival and no difference in the cumulative incidence of disease recurrence or deaths without recurrence between the 2 groups. At a median follow-up of 6.5 years there is no evidence of a plateau of progression-free survival. The majority of patients treated with donor lymphocyte infusions after relapse responded, demonstrating a significant graft-versus-leukemia effect in CLL. From these findings we have altered our approach for patients with high-risk CLL and are currently exploring the role of related and unrelated allogeneic SCT following reduced-intensity conditioning regimens.

AB - We report here on the long-term follow-up on 162 patients with high-risk chronic lymphocytic leukemia (CLL) who have undergone hematopoietic stem cell transplantation (SCT) at a single center from 1989 to 1999. Twenty-five patients with human leukocyte antigen (HLA)-matched sibling donors underwent T-cell-depleted allogeneic SCT, and 137 patients without HLA-matched sibling donors underwent autologous SCT. The 100-day mortality was 4% for both groups, but later morbidity and mortality were negatively affected on outcome. Progression-free survival was significantly longer following autologous than allogeneic SCT, but there was no difference in overall survival and no difference in the cumulative incidence of disease recurrence or deaths without recurrence between the 2 groups. At a median follow-up of 6.5 years there is no evidence of a plateau of progression-free survival. The majority of patients treated with donor lymphocyte infusions after relapse responded, demonstrating a significant graft-versus-leukemia effect in CLL. From these findings we have altered our approach for patients with high-risk CLL and are currently exploring the role of related and unrelated allogeneic SCT following reduced-intensity conditioning regimens.

UR - http://www.scopus.com/inward/record.url?scp=28844483804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28844483804&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-05-1778

DO - 10.1182/blood-2005-05-1778

M3 - Article

C2 - 16131571

AN - SCOPUS:28844483804

VL - 106

SP - 4389

EP - 4396

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -